by Manon FRACHON | 19 Feb Mon | English
Twelve week data from the Ph1b/2a AMARONE trial reveals Restoret to be well-tolerated in patients with diabetic macular edema and neovascular age-related macular degeneration. Proof of concept established with strong visual and anatomic outcomes. Treatment-naïve DME...
by Manon FRACHON | 4 Jan Thu | English
One year after its first investment, this new significant participation in HI-Bio™’s Series B financing, alongside major international investors, demonstrates the value creation already achieved by the company and underlines its attractiveness With this 6th...
by Manon FRACHON | 3 Jan Wed | English
Paris, France, 3 January 2024 – Jeito Capital (“Jeito”), a global leading independent private equity fund dedicated to biopharma, is pleased to announce the promotion of Ksenija Pavletic to Partner Investor. As part of the Jeito founding team with...
by Manon FRACHON | 3 Jan Wed | English
Paris, France, 3 January 2024 – Jeito Capital (“Jeito”), a global leading independent private equity fund dedicated to biopharma, is pleased to announce the un-stealthing [1] of its portfolio company Advesya, a pioneering biopharma company for...
by Manon FRACHON | 29 Nov Wed | English
Paris, France, November 29th 2023 – Jeito Capital (“Jeito”), a leading global investment company dedicated to biopharmaceuticals in Europe, is proud to announce the formation of its Special Advisors community composed of leading academic and industry experts...
by Manon FRACHON | 15 Nov Wed | English
Jeito Capital’s second round of funding will support NMD Pharma in becoming a leading, global, clinical-stage company, with a strong pipeline of breakthrough therapies for patients suffering from severe neuromuscular disorders. This funding round will also contribute...
Recent Comments